allogeneic cytomegalovirus-specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01475058)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenoviridae · Early Phase 1
- Cytomegalovirus · Early Phase 1
- Hematopoietic Stem Cell Transplantation · Early Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Organ Transplantation · Early Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Tissue Donors · Early Phase 1
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic cytomegalovirus-specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03665675 | Early Phase 1 (Phase 1) | Oct 1, 2018 | Ohio State University |
| NCT01475058 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | National Cancer Institute (NCI), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1